Medically Reviewed by: Dr. Michael Vines, MD – Medical Director, Camelback Recovery
You may be highly successful on paper yet internally exhausted by the constant effort it takes to manage your focus, impulses, and racing thoughts. Adult ADHD can affect much more than concentration. It can drain your energy, strain relationships, disrupt sleep, and make even simple responsibilities feel harder than they should.
Those challenges can become more complicated when anxiety, depression, or substance use is also part of your life.
Neurofeedback for ADHD offers a noninvasive way to practice self-regulation using real-time information about brain activity. Research is mixed, so we do not present neurofeedback as a cure. At Camelback Recovery, we may use it as one part of a broader plan built around your symptoms, recovery history, psychiatric needs, and daily functioning.
Want to understand whether neurofeedback may fit your current treatment plan? Call our Phoenix team at (602) 466-9880 to speak confidentially with admissions.
Our neurofeedback therapy in Phoenix can be integrated with broader mental health and dual-diagnosis care when clinically appropriate.
What Are We Actually Trying to Improve?
Neurofeedback at Camelback focuses on the everyday disruptions that can make adult ADHD exhausting.
- Focus & Task Engagement: Reinforcing activity associated with sustained attention to help you stay engaged and finish what you start.
- Impulse Control: Supporting a greater pause between a thought and an action when impulsive decisions create problems.
- Emotional Regulation: Practicing more regulated responses when frustration, stress, or overwhelm escalates quickly.
- Mental Restlessness: Helping you practice settling an active mind when it interferes with sleep, recovery, or concentration.
- Cognitive Performance: Supporting attention and processing while recognizing that neurofeedback does not correct every executive-function difficulty.
The CDC’s overview of adult ADHD notes that adults may experience challenges involving attention, organization, behavior control, task completion, and restlessness.
ADHD, Anxiety, and Substance Use: Why Dual Diagnosis Matters
ADHD does not always occur by itself.
You may also live with anxiety, depression, sleep problems, or a substance use disorder. These conditions can overlap and make it difficult to identify what is driving a specific symptom.
Difficulty concentrating may come from ADHD. It may also become worse during anxiety, depression, withdrawal, poor sleep, or early recovery.
Substance use adds another layer. Some adults may use alcohol or other substances while trying to manage restlessness, emotional discomfort, or sleep. Others may misuse prescription or illicit stimulants.
Those patterns should never be assumed, but they should be assessed when ADHD and substance use appear together.
A history of addiction also does not automatically rule out stimulant medication. Treatment decisions should consider recovery stability, misuse risk, current substance use, medication history, and psychiatric needs.
Our dual diagnosis treatment allows us to address mental health symptoms and substance use within one individualized plan. Neurofeedback can become another nonpharmacological tool within that larger approach.
Unsure whether your current ADHD treatment is enough? Verify your insurance benefits confidentially so our admissions team can explain your available coverage and treatment options.
What to Expect From ADHD Neurofeedback at Camelback
Your treatment starts with understanding what is actually interfering with your life.
We review your symptoms, medications, mental health history, previous treatment, substance use history when relevant, and personal goals.
During a session, small EEG sensors placed on your scalp passively record electrical brain activity. They do not send electricity into your brain.
You can then relax and interact with real-time visual or auditory feedback by watching a video, listening to music, or completing an interactive program. As selected brain activity occurs, the feedback changes immediately. A video may become clearer, music may adjust, or an interactive program may respond differently.
The goal is repeated practice with self-regulation rather than consciously controlling individual brain waves.
Accessible to clients coming from Phoenix, Scottsdale, and surrounding Valley communities, Camelback’s treatment environment emphasizes privacy, comfort, and individualized behavioral health care.
Your neurofeedback treatment may also coordinate with outpatient mental health treatment, psychiatry, addiction treatment, or other services when clinically appropriate.
How Many Sessions Might You Need?
Neurofeedback is a training process, so it generally involves repeated sessions.
Plans may fall within a rough range of 20 to 40 sessions. That is not a guaranteed treatment length or universal ADHD protocol.
Your schedule depends on your assessment, goals, response, recommended protocol, and other services involved in your care.
Setting Realistic Expectations About Neurofeedback for ADHD
Research on neurofeedback for ADHD is encouraging in some areas and less convincing in others.
A recent American Academy of Pediatrics evidence review found improvement across several neurofeedback studies, although researchers rated the overall strength of evidence as low.
A 2025 JAMA Psychiatry meta-analysis found no meaningful overall improvement in core ADHD symptoms under probably blinded assessments. However, small benefits appeared in studies using established standard protocols, along with a small improvement in processing speed.
The practical takeaway is straightforward.
Neurofeedback should not be sold as a cure for ADHD. Its potential value is as one tool that may support self-regulation, attention, and related functional concerns within a more comprehensive treatment plan.
Can Neurofeedback Replace ADHD Medication?
Treatment does not have to be either medication or neurofeedback.
Medication remains an established ADHD treatment. If it is helping you safely, neurofeedback does not automatically give you a reason to stop.
If medication provides only partial relief, causes difficult side effects, or raises concerns because of your substance use history, those issues deserve individualized clinical review.
Our outpatient psychiatry allows you to discuss ADHD symptoms, medication response, co-occurring mental health concerns, and substance-use considerations together.
You may also benefit from ongoing medication management for mental health when effectiveness, side effects, dosage, or medication changes need regular monitoring.
Do not stop or change prescribed ADHD medication without speaking with your prescribing clinician.
Neurofeedback for ADHD Within Whole-Person Treatment
Adult ADHD is not only about concentration.
The bigger problems may show up as missed deadlines, impulsive decisions, emotional exhaustion, poor sleep, strained relationships, or difficulty maintaining recovery routines.
When ADHD overlaps with anxiety or substance use, treating one diagnosis in isolation may leave important issues unresolved.
Neurofeedback gives us another noninvasive option to consider alongside psychiatric care, therapy, medication management, and dual-diagnosis treatment.
The goal is not to force one approach. It is to build a plan around what is still interfering with your life.
Ready to address ADHD, mental health, and recovery in one integrated plan? Call our Phoenix clinical team at (602) 466-9880.
Frequently Asked Questions (FAQs)
Research is mixed. Some studies report improvements, particularly with established neurofeedback protocols, while stronger blinded analyses have found more limited effects on core ADHD symptoms. We consider neurofeedback as one possible component of individualized care rather than guaranteeing a specific outcome.
It may be worth discussing. ADHD and substance use disorders can occur together, and neurofeedback provides a nonpharmacological option that can be considered within broader dual-diagnosis treatment.
A substance-use history does not automatically rule out ADHD medication. Your prescriber should consider your diagnosis, recovery status, misuse risk, medication history, and monitoring needs before making a recommendation.
There is no universal number that guarantees improvement. Plans may involve roughly 20 to 40 sessions, but your schedule depends on your goals, protocol, response, and other treatment.
Adults have been included in neurofeedback research, although much of the evidence focuses on children and adolescents. Your symptoms, previous treatment, and functional challenges should guide whether neurofeedback is worth considering.
Coverage varies significantly by insurer, policy, diagnosis, and medical-necessity requirements. Some insurance plans may limit or exclude coverage for EEG neurofeedback, while coverage under other plans depends on the specific benefits and authorization requirements.
Our admissions team can complete a confidential verification of benefits and explain your estimated coverage and potential out-of-pocket responsibility before treatment begins. Verification provides an estimate of benefits and does not guarantee that your insurer will ultimately pay a claim.
Sources
- Centers for Disease Control and Prevention. (2024). ADHD in adults. https://www.cdc.gov/adhd/about/adhd-in-adults.html
- Peterson, B. S., Trampush, J., Maglione, M., et al. (2024). Treatments for ADHD in children and adolescents: A systematic review. Pediatrics, 153(4), e2024065787. https://doi.org/10.1542/peds.2024-065787
- U.S. Department of Veterans Affairs, Health Systems Research. (2024). ADHD and substance use disorders in adults: A systematic review. https://hsrd.research.va.gov/publications/esp/adult-adhd.cfm
- Westwood, S. J., Aggensteiner, P.-M., Kaiser, A., Nagy, P., Donno, F., Merkl, D., Balia, C., Goujon, A., Bousquet, E., Capodiferro, A. M., Derks, L., Purper-Ouakil, D., Carucci, S., Holtmann, M., Brandeis, D., Cortese, S., & Sonuga-Barke, E. J. S. (2025). Neurofeedback for attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Psychiatry, 82(2), 118–129. https://doi.org/10.1001/jamapsychiatry.2024.3702